Analysis of oncology clinical pharmacology studies authorized by the national regulatory agency of Argentina between 2018 and 2022
DOI:
https://doi.org/10.62035/rca.4.41Keywords:
clinical trials, oncology, study characteristicsAbstract
The traditional paradigm of pharmacological clinical research involves carrying out phase 1, 2, and 3 studies. However, the recent advance of what has been called “precision medicine” has promoted the emergence of innovations in the design of clinical trials, especially in the area of oncology. The purpose of this article is to describe and characterize oncology clinical pharmacology studies authorized by the National Administration of Drugs, Food and Medical Devices (ANMAT) during the period from August 2018 to July 2022, and analyze the status of the clinical trial designs, research phases, investigational products and tumor site locations concerning the advancement of precision medicine and innovative designs.
References
Hobbs BP, Barata PC, Kanjanapan Y, Paller CJ, Perlmutter J, Pond GR, et al. Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology. Journal of the National Cancer Institute. 2019;111(2):118–128.
Renfro LA, Sargent DJ. Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples. Annals of Oncology 2017;28(1):34–43.
Ou FS, An MW, Ruppert AS and Mandrekar SJ. Discussion of Trial Designs for Biomarker Identification and Validation Through the Use of Case Studies. JCO Precision Oncology. 2019;(3):1–10.
Carrasco Rubio L, Pérez Fernández MI. Diseño y monitorización de ensayos clínicos oncológicos basados en biomarcadores. Dianas. 2020;9(2):1-11.
Department of Health and Human Services Food and Drug Administration [Internet]. Master Protocols: Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics Guidance for Industry. U.S. [actualizada marzo 2022; citada marzo 2023]. Disponible en:https://www. fda.gov/media/120721/download.
European Medicines Agency (EMA) [Internet]. Guideline on multiplicity issues in clinical trial. 2016 [actualizada junio 2017; citada marzo 2023]. Disponible en: https://www.ema.europa.eu/ en/documents/scientific-guideline/draft-guideline-multiplicityissues-clinical-trials_en.pdf.
European Medicines Agency (EMA) [Internet]. Reflection paper on Methodological Issues in Confirmatory Clinical Trials Planned with an Adaptive Design. [actualizada octubre 2007; citada marzo 2023]. Disponible en:https://www.ema.europa. eu/en/documents/scientific-guideline/reflection-papermethodological-issues-confirmatory-clinical-trials-plannedadaptive-design_en.pdf.
European Medicines Agency (EMA) [Internet]. Guideline on the investigation of subgroups in confirmatory clinical trials [actualizada enero 2019; citada marzo 2023]. Disponible en:https://www.ema.europa.eu/en/documents/scientificguideline/guideline-investigation-subgroups-confirmatoryclinical-trials_en.pdf.
Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT) [Internet]. Disposición 6677/10. Régimen de Buena Práctica Clínica para estudios de farmacología clínica [actualizada noviembre 2010; citada marzo 2023]. Disponible en: https://www.argentina.gob.ar/normativa/ nacional/disposici%C3%B3n-6677-2010-174557.
Huber M, Huber B. Innovation in Oncology Drug Development. Journal of Oncology. 2019;2019:1-16.
Traversi L, González ML, Murias MA, et al. Protocolos Maestros: Enfoque Regulatorio de Nuevos Diseños en Ensayos de Farmacología Clínica. Revista Ciencia Reguladora. 2019;3(5):19-25.
Sánchez Pérez MJ y Vicente Baz DD. Nuevas terapias en oncología: revisión descriptiva. Bol Ter ANDAL. 2020;35(3):22-38.
Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409(6822):860- 921.
Janiaud P, Serghiou S, Ioannidis JPA. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology. Cancer Treat Rev. 2019;73:20-30.
Tsimberidou AM, Fountzilas E, Nikanjam M, Kurzrock R. Review of Precision Cancer Medicine: Evolution of the Treatment Paradigm. Cancer Treat Rev. 2020; 86:102019.
Garralda E, Dienstmann R, Piris-Giménez A, Braña I, Rodon J, Tabernero J. New clinical trial designs in the era of precision medicine. New clinical trial designs in the era of precision medicine. Molecular Oncology. 2019;13(3):549–557.
Redig AJ, Jänne PA. Basket trials and the evolution of clinical trial design in an era of genomic medicine. J Clin Oncol. 2015;33(9):975–977.
Simon R, Geyer S, Subramanian J, Roychowdhury S. The Bayesian basket design for genomic variant-driven phase II trials. Semin Oncol. 2016;43(1):13–18.
Klauschen F, Andreeff M, Keilholz U, et al. The combinatorial complexity of cancer precision medicine. Oncoscience. 2014;1(7):504–509.
Woodcock J and LaVange LM. Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. N Engl J Med. 2017;377:62-70.
Spreafico A, Hansen AR, Abdul Razak AR et al. The Future of Clinical Trial Design in Oncology. Cancer Discov. 2021;11:822–37.
Falcone R, Lombardi P, Filetti M, et al. Oncologic Drugs Approval in Europe for Solid Tumors: Overview of the Last 6 Years. Cancers. 2022;14,889.
Scott EC, Gong Y, Subedee A, et al. Emerging oncology drug targets in the 21st century: An FDA analysis. Journal of Clinical Oncology. 2020.
IMS Institute for Healthcare Informatics [Internet]. Global Oncology Trend Report: A Review of 2015 and Outlook to 2020. [actualizada 2016; citada marzo 2023]. Disponible en: https://es.scribd.com/document/323179495/IMSH-Institute-GlobalOncology-Trend-2015-2020-Report#.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles published are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
This permits anyone to copy, redistribute, remix, transmit, and adapt the work provided the original work and source are appropriately cited.
